Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 12/20 | 0.75 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.75 |
| ▸ | TCF7 | P36402 | 2/20 | 0.75 |
| ▸ | BCL9 | O00512 | 1/20 | 0.75 |
| ▸ | TCF4 | P15884 | 1/20 | 0.75 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557085 | 0.90 | CLPP (0.61) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL178745 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677335 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865605 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865597 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL29352986 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL19833048 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13744871 | 0.86 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13745272 | 0.84 | CLPP (0.85) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL25352785 | 0.83 | CLPP (0.72) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | CLPP 2860/4885CTNNB1 206/4885TCF7 258/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | CLPP 2763/4885CTNNB1 2/4885TCF7 33/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | CLPP 2763/4885CTNNB1 2/4885TCF7 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.